Navigation Links
InVitria Touts Product Advantages at Cambridge's Cell Culture Conference
Date:9/24/2008

FORT COLLINS, Colo., Sept. 24 /PRNewswire/ -- InVitria (http://www.InVitria.com) addressed attendees at Cambridge Healthtech Institute's 4th Annual "Optimizing Cell Culture Development" Conference on September 15-16 in Boston, Massachusetts and announced its most recent results optimizing cell culture media using its product line of animal free cell culture ingredients. (http://www.healthtech.com/ocb/overview.aspx?c=562)

In a presentation of scientific studies with InVitria's Cellastim and Lacromin, Steve Pettit, Director of InVitria's Cell Culture Group, noted, "The growth and productivity results in CHO cell lines are quite impressive and not achievable with other sources of albumin or transferrin supplements. Cellastim has shown growth and productivity up to 50% better than the next best alternative. Similar impressive results with the use of Lacromin have previously been published by our team(1)," said Pettit.

"We continue to show powerful results of Cellastim and Lacromin in cell culture media for a variety of cell lines including CHO, Hybridoma, Vero and NS0 cells. Since these are well defined supplements, they help our customers achieve both their regulatory and manufacturing goals. These are the only supplements available that not only improve cell culture performance, but do this while maintaining a defined and animal free media," said Scott Deeter, InVitria's President.

About InVitria (http://www.InVitria.com)

InVitria has developed animal free cell culture ingredients that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry. InVitria's animal free product line includes:

-- Cellastim - Cellastim is a recombinant albumin that is used as a cell culture ingredient and biopharmaceutical formulation excipient. Cellastim has been shown to improve mammalian cell culture productivity. Cellastim also has been an effective component in stem cell media and primary cell media.(see http://www.Cellastim.com)

-- Lacromin - Lacromin is recombinant human lactoferrin, a growth factor that also delivers iron similar to transferrin in cell culture media. (see http://www.Lacromin.com)

-- Lysobac - Lysobac is a bacterial cell lysis agent that is more efficient and more consistent compared to chicken lysozyme and provides higher recombinant protein yield compared with mechanical cell lysis. Lysobac is used in bacterial fermentation to improve recombinant protein yields.(see http://www.Lysobac.com)

(1) Huang et al. Bioactive Recombinant Human Lactoferrin Stimulates Mammalian Cell Growth. Society for InVitro Biology. InVitro Cell Develop. Biology. May 6, 2008.

For more information about the InVitria line of products, please e-mail info@InVitria.com or call 1-800-916-8311.


'/>"/>
SOURCE InVitria
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InVitria Sponsors Cambridge Healthtechs Optimizing Cell Culture Development Conference
2. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
3. InVitria Expands Sales Team
4. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
5. Gores Legacy of Innovation Extends From Products to Processes
6. Martek is Now the Sole-Source Supplier of ARA for all Infant Formula Products Manufactured by Hochdorf Nutricare
7. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
8. Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment
9. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
10. 2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expos 14-Year History
11. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. ... San Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, ... government officials from around the world to address key issues in device compliance, quality ...
(Date:10/11/2017)... Georgia (PRWEB) , ... October 11, 2017 , ... Disappearing ... taking the lives of over 5.5 million people each year. Especially those living in ... greenovative startup Treepex - based in one of the most pollution-affected countries globally - ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
Breaking Biology Technology:
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):